Live Breaking News & Updates on Corvus Pharmaceuticals Company Profile

Stay updated with breaking news from Corvus pharmaceuticals company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Insider Buying: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Buys $34,600.00 in Stock

Insider Buying: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Buys $34,600.00 in Stock
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

William Benton Jones , Securities Exchange Commission , Corvus Pharmaceuticals Stock , Corvus Pharmaceuticals Company Profile , Corvus Pharmaceuticals Inc , Hedge Funds Weigh In On Corvus Pharmaceuticals , Cantor Fitzgerald , Corvus Pharmaceuticals , News Ratings For Corvus Pharmaceuticals Daily , Get Free Report , Free Report , Corvus Pharmaceuticals Daily ,

Corvus Pharmaceuticals (CRVS) Set to Announce Earnings on Monday

Corvus Pharmaceuticals (CRVS) Set to Announce Earnings on Monday
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

News Ratings For Corvus Pharmaceuticals Daily , Corvus Pharmaceuticals Company Profile , Earnings History For Corvus Pharmaceuticals , Corvus Pharmaceuticals , Cantor Fitzgerald , Corvus Pharmaceuticals Inc , Corvus Pharmaceuticals Stock Performance , Get Free Report , Corvus Pharmaceuticals Daily ,

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,490,000 shares, an increase of 17.3% from the February 29th total of 1,270,000 shares. Based on an average daily trading volume, of 218,100 […] ....

Corvus Pharmaceuticals Stock Performance , Tucker Asset Management , Corvus Pharmaceuticals Inc , Cantor Fitzgerald , Renaissance Technologies , News Ratings For Corvus Pharmaceuticals Daily , Corvus Pharmaceuticals Company Profile , Corvus Pharmaceuticals , Institutional Trading Of Corvus Pharmaceuticals , Tower Research Capital , Charles Schwab Investment Management Inc , Get Free Report , Research Capital , Street Corp , Asset Management , Charles Schwab Investment Management , Corvus Pharmaceuticals Daily , Nasdaq Crvs ,

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Vanguard Group Inc , Tucker Asset Management , Corvus Pharmaceuticals Company Profile , Corvus Pharmaceuticals Trading , Corvus Pharmaceuticals , Corvus Pharmaceuticals Inc , American Century Companies Inc , News Ratings For Corvus Pharmaceuticals Daily , Goldman Sachs Group Inc , Get Free Report , Century Companies , Asset Management , Goldman Sachs Group , Corvus Pharmaceuticals Daily ,

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above 50-Day Moving Average of $1.43

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.43 and traded as high as $1.54. Corvus Pharmaceuticals shares last traded at $1.51, with a volume of 105,012 shares traded. Analyst Ratings Changes A number […] ....

Corvus Pharmaceuticals , Charles Schwab Investment Management Inc , Cantor Fitzgerald , Tower Research Capital , Institutional Trading Of Corvus Pharmaceuticals , Corvus Pharmaceuticals Company Profile , York Mellon Corp , Corvus Pharmaceuticals Price Performance , Virtu Financial , Tucker Asset Management , Corvus Pharmaceuticals Inc , News Ratings For Corvus Pharmaceuticals Daily , Get Free Report , Asset Management , Schwab Investment Management , Research Capital , New York Mellon Corp , Corvus Pharmaceuticals Daily , Nasdaq Crvs ,